ClinicalTrials.Veeva

Menu

Feasibility and Acceptability of Non Weight-bearing Physical Activity for People With Diabetic Foot Ulceration (DB-ACTIV)

U

Université du Québec à Trois-Rivières

Status

Active, not recruiting

Conditions

Cardiopulmonary
Physical Inactivity
Diabetic Foot

Treatments

Behavioral: Non weight-bearing physical activity program

Study type

Interventional

Funder types

Other

Identifiers

NCT06092827
F11-3298 : DB-ACTIV

Details and patient eligibility

About

Intervention in the form of a PA (physical activity) program combining aerobic, resistance, and flexibility exercises adapted for wearing a lower limb offloading device and limiting weight-bearing on the feet, with a duration of twelve (12) weeks, consisting of two supervised sessions and one unsupervised home session per week.

Full description

Objectives:

  1. Evaluate the acceptability of a non-weight bearing physical activity (PA) program;
  2. Assess the feasibility of the PA program and the data collection procedure;
  3. Evaluate the feasibility of a submaximal exercise test for cardiorespiratory capacity; and
  4. Verify the sensitivity of dependent variables to respond to a physical activity program (e.g., cardiorespiratory capacity, cardiovascular and metabolic risk factors, quality of life, PA level).

Type of study:

Feasibility and acceptability study with a pre-post evaluative design.

Intervention:

Intervention in the form of a PA (physical activity) program combining aerobic, resistance, and flexibility exercises adapted for wearing a lower limb offloading device and limiting weight-bearing on the feet, with a duration of twelve (12) weeks, consisting of two supervised sessions and one unsupervised home session per week.

Subjects:

  • 10-12 persons with an active diabetic foot ulcer
  • 2-3 kinesiologists

Data collection:

  • Sociodemographic and health questionnaire (age, sex, gender, marital status, education level, employment status, average annual family income, medical and health history, pharmacological and non-pharmacological treatments);

  • Feasibility assessment: PA (physical activity) logbook including 1) the number of supervised and unsupervised sessions completed, 2) the duration of each session, 3) participation rate (number of patients recruited/number of eligible patients), 4) attrition rate (number of participants who completed the follow-ups/number of participants recruited), and 5) perceived facilitators and barriers;

  • Acceptability assessment: 1) Treatment Acceptability and Preference (TAP) Questionnaire, seven to nine additional questions to assess the use of provided material resources and required safety checks (capillary blood glucose and wound inspection) and collection of participants' feedback, and 2) Client Satisfaction Questionnaire (CSQ-8);

  • Assessment of the sensitivity of dependent variables to respond to the PA program*: 1) estimation of VO2max by a submaximal exercise test on a stationary bike (Aerobic Power Index submaximal exercise test), 2) average daily step count over seven days at the waist and in the offloading boot at times 0, 4, 8, and 12 weeks, 3) Global Physical Activity Questionnaire (GPAQ), 3) clinical examination (height, weight, body mass index, waist circumference, body fat percentage, blood pressure, resting heart rate, characteristics of the DFU and classification (SINBAD), 4) paraclinical examinations (venous blood glucose, glycated hemoglobin, lipid profile), 5) neuropathic pain questionnaire (DN4), 6) Epworth sleepiness scale, quality of life questionnaire (EQ-5D-5L), 7) questionnaire on motivation to practice PA.

  • Health and safety parameter measurements: electrocardiogram, oxygen saturation, estimated glomerular filtration rate, urine albumin/creatinine ratio, complete blood count.

    • Data collection at 24 and 36 weeks is also planned for participants who agree to be contacted after completing the 12-week PA program.

Enrollment

12 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

For individuals with a diabetic foot ulcer:

Inclusion:

  • Male or female
  • Aged over 18 up to 75 years
  • Willing to engage in PA (physical activity)
  • Committed to following wound care recommendations to the best of their ability for the duration of the study
  • Understand and read French.

Exclusion:

  • Uncontrolled DFU infection
  • Use of a non-removable offloading modality (total contact cast)
  • Uncontrolled hyperglycemia (HbA1c ≥ 10.0% or fasting blood glucose ≥ 16.0 mmol/L for ≥ 2 consecutive days) confirmed by blood sample results during the initial assessment or access to recent blood test results (within the last 3 months) or the log of home capillary blood glucose readings
  • Participation in sports or regular intense physical activities (≥ 2 times per week)
  • The following pre-existing heart problems: a cardiovascular event (myocardial infarction, heart surgery, etc.) in the last 3 months, unstable cardiovascular disease (uncontrolled hypertension, i.e., ≥ 160/90 mmHg, uncompensated heart failure, etc.), chest pain and exertional dyspnea and/or uninvestigated intermittent claudication
  • Recent neurovascular problem (stroke, transient ischemic attack, etc.) in the last 3 months
  • Health problem that the research team considers a contraindication to participating in the study
  • Diabetes complication making moderate-intensity PA unsafe, such as untreated proliferative diabetic retinopathy or a sensitivity disorder to hypoglycemia, critical ischemia of one or both lower limbs.

For kinesiologists:

Inclusion:

  • Have completed a bachelor's degree in kinesiology
  • Understand, read, and speak French.

Exclusion:

None

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

12 participants in 1 patient group

Physical activity
Experimental group
Description:
Adults 18 to 75 with an active diabetic foot ulcer
Treatment:
Behavioral: Non weight-bearing physical activity program

Trial contacts and locations

1

Loading...

Central trial contact

Magali Brousseau-Foley, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems